Panthera Biosciences (Panthera) has secured £10 million of investment from BGF and Gresham House Ventures, the latter investing on behalf of the Baronsmead VCTs.
This investment will allow Panthera to further grow its network of dedicated clinical trial sites across the UK and Western Europe. Since launching in late 2019, with an initial investment from Gresham House Ventures and Catapult in 2020, Panthera has grown to become a major player in the UK with nine sites and a rapidly growing order book.
This investment round will be used to fund further expansion in the UK and Western Europe, as well as continuing to invest in enhancing the service offering.
